Clinical trial · Interventional
Using 3D Kidney Model Based on Artificial Intelligence to Assist Partial Nephrectomy: A Prospective Validation Study
Artificial Intelligence-Driven 3D Kidney Model for Real-Time Augmented Reality and Surgical Navigation in Minimally Invasive (Robotic/Laparoscopic) Partial Nephrectomy: A Prospective Validation Study
NCT07020169CI-TRIAL-00090974recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to develop a real-time artificial intelligence-driven 3D kidney model to assist robotic or laparoscopic partial nephrectomy: • Can this AI-powered model optimize the workflow of partial nephrectomy and enhance surgical benefits?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Cancer | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| an AI-based real-time image-guided kidney model system | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Conventional Surgical Approaches
- description
- perform conventional laparoscopic or robotic-assisted surgical approaches
- type
- EXPERIMENTAL
- label
- AI model group
- description
- Use the AI-model to locate kidney and tumour, assisting surgeon with the operation
- interventionNames
- Procedure: an AI-based real-time image-guided kidney model system
Primary outcomes (1)
- measure
- Operative Time
- timeFrame
- Intraoperative
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Ages 18-80 years, regardless of gender * Written informed consent obtained from the patient or legally authorized representative after full protocol disclosure * Preoperative imaging (CT/MRI) confirming clinical stage T1a or select T1b renal tumors suitable for partial nephrectomy (R.E.N.A.L. nephrometry score ≤10) * Localized renal tumors without lymph node/distant metastasis per NCCN Guidelines® (v2023) * Elective minimally invasive partial nephrectomy (laparoscopic/robotic) after comprehensive surgical counseling Exclusion Criteria: * Multifocal renal tumors (bilateral or unilateral) * Prior systemic anticancer therapy (targeted agents/immunotherapy/chemotherapy) within 6 months * Absolute surgical contraindications (e.g., ASA class ≥IV, uncontrolled coagulopathy) * Intraoperative conversion to radical nephrectomy or open approach * Postoperative adjuvant therapy during protocol-defined follow-up (12 months) * Major comorbidities (e.g., NYHA class III/IV heart failure, eGFR \<30 mL/min/1.73m²) affecting outcome assessment * Concurrent enrollment in interventional clinical trials * Investigator-determined ineligibility based on risk-benefit analysis
References
Publications (0)
Data not yet available
No reference posted for this study.